This review assessed clinical outcomes of pre-, pro-and synbiotics therapy in patients with acute pancreatitis, and found no significant effect and a lack of evidence supporting their use in this area. The authors' conclusions reflect the lack of high quality evidence available and their recommendation, that further well-designed RCTs are needed, appears appropriate.
Study selection
Eligible studies were randomised controlled trials (RCTs) that evaluated the use of prebiotics, probiotics or synbiotics in patients with acute pancreatitis. Eligible trials had to report at least one of a pre-specified range of mortality and morbidity outcomes including number of infections, number of pancreatic infectious complications, number of multiple organ failures and systemic inflammation response syndromes, surgical interventions, length of hospital stay, and mortality.
In included trials, the duration of treatment ranged from seven days (most trials) to 28 days (one trial). Over half of the included trials used enteral nutrition as a control group. A wide range of pre-, pro-, and synbiotics were used in included trials. Most trials reported mean or range of APACHE II (second acute physiology and chronic health evaluation) patient characteristics, and mean C-Reactive Protein; one trial used the Glasgow score and one trial used the Imrie score. Included trials were published between 2002 and 2009. Trials were conducted in China, the UK, Turkey and the Netherlands. Adverse effects were reported in some trials.
The authors did not state how many reviewers selected studies for inclusion.
Assessment of study quality
Trial risk of bias was assessed using the Jadad scale, awarding a score out of 5 points based on adequacy of randomisation, allocation concealment, blinding and follow-up.
The authors did not state how many reviewers performed quality assessment.
Data extraction
Two authors independently extracted data required to calculate odds ratios (ORs) with 95% confidence intervals (CIs) for dichotomous outcomes, or mean differences with 95% confidence intervals for continuous outcomes. If more than one paper reported data from the same trial, data from the most recent trial was extracted. Disagreements were resolved by consensus.
Methods of synthesis
Odds ratios with 95% confidence intervals (for dichotomous outcomes) and mean differences with 95% confidence intervals (for continuous outcomes) were pooled using fixed-effect models if no statistical heterogeneity was identified; random-effects models were used if statistical heterogeneity was identified. Statistical heterogeneity was assessed using the χ 2 statistic (and considered present if p<0.05) and quantified using the I 2 index.
